Cardiovascular

FDA issues safety communication on interactions between statins and protease inhibitors

On March 1, the U.S. Food and Drug Administration (FDA) released a safety communication consisting of updated commendations concerning drug-drug interactions between statins and protease inhibitors. Taking the two types of drugs can increase the blood level of the statin and increase the risk for myopathy, including rhabdomyolysis. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares